ATE470439T1 - Verwendung von hif 1alfa modulatoren zur behandlung von krebs - Google Patents

Verwendung von hif 1alfa modulatoren zur behandlung von krebs

Info

Publication number
ATE470439T1
ATE470439T1 AT06784964T AT06784964T ATE470439T1 AT E470439 T1 ATE470439 T1 AT E470439T1 AT 06784964 T AT06784964 T AT 06784964T AT 06784964 T AT06784964 T AT 06784964T AT E470439 T1 ATE470439 T1 AT E470439T1
Authority
AT
Austria
Prior art keywords
1alfa
hif
modulators
treat cancer
treating
Prior art date
Application number
AT06784964T
Other languages
English (en)
Inventor
Todd Seeley
David Liu
Stephen Klauss
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE470439T1 publication Critical patent/ATE470439T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT06784964T 2005-06-15 2006-06-15 Verwendung von hif 1alfa modulatoren zur behandlung von krebs ATE470439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69100605P 2005-06-15 2005-06-15
PCT/US2006/023399 WO2006138511A2 (en) 2005-06-15 2006-06-15 Use of hif 1alfa modulators for treatment of cancer

Publications (1)

Publication Number Publication Date
ATE470439T1 true ATE470439T1 (de) 2010-06-15

Family

ID=37571192

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06784964T ATE470439T1 (de) 2005-06-15 2006-06-15 Verwendung von hif 1alfa modulatoren zur behandlung von krebs

Country Status (14)

Country Link
US (1) US8530404B2 (de)
EP (1) EP1919463B9 (de)
JP (2) JP5410751B2 (de)
KR (1) KR20080028918A (de)
CN (1) CN101242817B (de)
AT (1) ATE470439T1 (de)
AU (1) AU2006259352A1 (de)
BR (1) BRPI0611670A2 (de)
CA (1) CA2611785A1 (de)
DE (1) DE602006014843D1 (de)
HK (1) HK1117422A1 (de)
IL (1) IL188101A (de)
MX (1) MX2007016160A (de)
WO (1) WO2006138511A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1644336T3 (da) 2003-06-06 2011-05-09 Fibrogen Inc Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
WO2006133391A2 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
EP2476669A1 (de) 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisochinolinverbindungen und Verfahren zu deren Verwendung
EP1991269A1 (de) 2006-02-16 2008-11-19 Fibrogen, Inc. Verbindungen und verfahren zur behandlung von apoplexie
JP5111491B2 (ja) * 2006-04-04 2013-01-09 フィブロジェン， インコーポレイテッド ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法
US20070293575A1 (en) * 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) * 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
LT3357911T (lt) 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolilo hidroksilazės inhibitoriai ir naudojimo būdai
AU2007334323B2 (en) * 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
AU2007334321B2 (en) 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2442847T3 (es) * 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
US7569726B2 (en) * 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
EP2155746A2 (de) * 2007-05-04 2010-02-24 Amgen, Inc Diazachinolone zur hemmung der prolylhydroxylaseaktivität
EP2150251B9 (de) * 2007-05-04 2013-02-27 Amgen, Inc Thienopyridin- und thiazolopyridin-derivate zur hemmung der aktivität von prolylhydroxylase
WO2008157177A1 (en) * 2007-06-13 2008-12-24 The Uab Research Foundation Methods for modulating osteoblast cell differentiation and bone generation through inhibition of a prolyl hydroxylase
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2231156A1 (de) * 2007-12-07 2010-09-29 Fibrogen, Inc. Verfahren zur vermehrung von weissen blutkörperchen
EP2252619B1 (de) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazolpyridinderivate als modulatoren der hif-(hypoxia-inducible-factor-)aktivität
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
AU2012268400C1 (en) * 2011-06-06 2016-12-22 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (de) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP2785872A4 (de) * 2011-12-01 2015-12-09 Univ Ohio State Materialien und verfahren im zusammenhang mit nsaid-chemoprävention bei kolorektalkrebs
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
WO2014014834A1 (en) 2012-07-16 2014-01-23 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3470397B1 (de) 2012-07-16 2021-12-29 Fibrogen, Inc. Kristalline formen eines prolylhydroxylaseinhibitors
DK2951159T3 (en) 2013-01-24 2018-11-19 Fibrogen Inc CRYSTALLIC FORMS OF {[1-CYANO-5- (4-CHLORPHENOXY) -4-HYDROXY-ISOQUINOLIN-3-CARBONYL] -AMINO} ACETIC ACID
ES2786924T3 (es) 2013-06-06 2020-10-14 Fibrogen Inc Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF
CA3151685A1 (en) 2013-06-13 2014-12-18 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
SI3277270T1 (sl) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Sestavki in postopki za zdravljenje anemije
US11124483B2 (en) 2015-09-02 2021-09-21 The Regents Of The University Of California HER3 ligands and uses thereof
WO2017110791A1 (ja) 2015-12-21 2017-06-29 株式会社東京精密 切断用ブレードの製造方法、及び切断用ブレード
CN107115355B (zh) * 2017-05-26 2020-01-17 昆明医科大学 一种含有无机砷化合物的药物组合物及其应用
WO2019138084A1 (en) * 2018-01-11 2019-07-18 Institut Pasteur Phenanthrolinone derivatives for use in the treatment of bacterial infections
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US5916898A (en) 1997-10-24 1999-06-29 Zeneca Limited Phenanthroline derivatives
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
EP1027351B1 (de) 1997-10-24 2003-12-03 Fibrogen, Inc. Phenanthrolin-derivate
EP1034267A1 (de) * 1997-12-04 2000-09-13 Genzyme Corporation Verbindungen und methoden zur induktion der genexpression
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
US6506936B1 (en) 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
GB9911047D0 (en) 1999-05-12 1999-07-14 Isis Innovation Assay method and means
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
US7396922B2 (en) 2001-11-28 2008-07-08 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense Inhibitory PAS domain protein
EP2324834B1 (de) * 2001-12-06 2019-05-08 Fibrogen, Inc. Verfahren zur Steigerung des endogenen Erythropoietins
HUP0500103A3 (en) 2001-12-19 2009-01-28 Ortho Mcneil Pharm Inc Tetracyclic compounds containing oxygen and/or sulfur atom, process for the preparation of some of them, their use and pharmaceutical compositions containing them
GB0211920D0 (en) * 2002-05-23 2002-07-03 Isis Innovations Ltd Assay
KR20050083855A (ko) * 2002-11-01 2005-08-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
US20060251638A1 (en) * 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
DK1644336T3 (da) 2003-06-06 2011-05-09 Fibrogen Inc Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
WO2006010920A1 (en) 2004-07-30 2006-02-02 Isis Innovation Limited Soluble polypeptide

Also Published As

Publication number Publication date
CA2611785A1 (en) 2006-12-28
MX2007016160A (es) 2008-03-07
CN101242817A (zh) 2008-08-13
US8530404B2 (en) 2013-09-10
JP2008543864A (ja) 2008-12-04
DE602006014843D1 (de) 2010-07-22
JP2014012690A (ja) 2014-01-23
EP1919463A2 (de) 2008-05-14
AU2006259352A1 (en) 2006-12-28
HK1117422A1 (en) 2009-02-13
WO2006138511A3 (en) 2007-03-29
US20070004627A1 (en) 2007-01-04
EP1919463B9 (de) 2011-02-02
IL188101A (en) 2012-10-31
WO2006138511A2 (en) 2006-12-28
EP1919463B1 (de) 2010-06-09
IL188101A0 (en) 2008-04-13
JP5410751B2 (ja) 2014-02-05
KR20080028918A (ko) 2008-04-02
BRPI0611670A2 (pt) 2016-11-16
CN101242817B (zh) 2016-08-31

Similar Documents

Publication Publication Date Title
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
RU2448096C3 (ru) Диарилгидантоины
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
SG155163A1 (en) Pharmacokinetically improved compounds
TW200801008A (en) Protein kinase inhibitors
DE602007012677D1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
EA201590262A1 (ru) Комбинированное лечение меланомы, включающее введение кобиметиниба и вемурафениба
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
EA201100874A1 (ru) Соединения для лечения рака
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
TW200716132A (en) Novel chemical compounds
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
WO2009154790A8 (en) Novel metastasis suppressor genes and uses thereof
TW200716579A (en) Novel chemical compounds
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties